India.com News Desk | Aug 22, 2021, 10:18 AM IST
Zydus Cadila's indigenously developed needle-free three-dose COVID-19 vaccine ZyCoV-D was granted emergency use authorisation (EUA) by the drug regulator on Friday, making it the first vaccine to be administered to beneficiaries in the age group of 12-18 years in the country.
India.com News Desk | Aug 10, 2021, 7:50 PM IST
The DCGI has said that the study and its clinical trials will be conducted by Christian Medical College in Vellore.
India.com News Desk | Jul 9, 2021, 2:54 PM IST
Hetero had entered into a non-exclusive licensing agreement with MSD in April this year, to manufacture and supply Molnupiravir in India and over 100 low and middle-income countries (LMICs).
India.com News Desk | Jul 2, 2021, 7:16 AM IST
. India's drug regulator had last month granted permission for restricted emergency use of the Russian COVID-19 vaccine Sputnik V with certain conditions.
India.com News Desk | Jul 1, 2021, 8:46 AM IST
The development comes as a great relief for children who are waiting to be vaccinated amidst the possibility of the third wave of Covid-19, which experts have warned may affect the kids primarily.
India.com News Desk | Jun 29, 2021, 5:52 PM IST
As per updates, the DCGI has granted permission as per the provisions of the New Drugs and Clinical Trial Rules , 2019 under Drugs and Cosmetics Act, 1940.
India.com News Desk | Jun 4, 2021, 9:26 PM IST
According to the four conditions set by the DCGI, the Serum Institute will have to submit a copy of the agreement between it and the Gamaleya Research Institute of Epidemiology and Microbiology for transfer of cell bank and virus stock and submit the copy of agreement for technology transfer with Gamaleya.
India.com News Desk | Jun 2, 2021, 11:01 AM IST
Coronavirus vaccines like Pfizer and Moderna, which had requested the government for waivers no longer need to undergo post-approval bridging trials for supply in the country.
India.com News Desk | Jan 10, 2021, 12:03 AM IST
The much-awaited Coronavirus vaccination drive in India will begin on January 16, 2021, the Centre confirmed on Saturday.
India.com News Desk | Jan 3, 2021, 1:24 PM IST
"Vaccines are 110 per cent safe. Some side effects like mild fever, pain and allergy are common for every vaccine", said DCGI.
India.com News Desk | Jan 3, 2021, 11:18 AM IST
"Vaccines of Serum Institue of India and Bharat Biotech are granted permission for restricted use in emergency situation", said DCGI's Dr VG Somani today.
India.com News Desk | Jan 3, 2021, 12:03 AM IST
The central government plans to vaccinate nearly 30 crore people in the first phase of drive in the next six to eight months.
English
